Printer Friendly

Invasive fungal rhinitis caused by Paecilomyces lilacinus infection: report of a case and a novel treatment.

Abstract

Invasive fungal infections of the sinonasal tract are a rare but known entity in immunocompromised patients. Paecilomyces lilacinus is a nematophagous fungi with septate hyphae that has afflicted humans in multiple forms, causing cutaneous, ocular, and sinonasal infections. Only 4 cases of P lilacinus and 2 cases of Paecilomyces variotii in the sinonasal tract have been reported in the literature. We present a case of invasive fungal rhinitis secondary to P lilacinus infection in an immunocompromised patient. She was managed successfully with a novel treatment: voriconazole and endonasal microdebridement.

Introduction

Fungal infection with Paecilomyces lilacinus has been reported in humans in multiple forms. Cutaneous hyalohyphomycosis, vaginitis, endophthalmitis, fungemia, onychomycosis, keratitis, and bursitis have all been reported. (1-7) In addition, 4 cases of sinonasal tract P lilacinus infection and 2 cases of sinonasal Paecilomyces variotii have been reported. (8-12) Of the 4 cases of the former, none was an isolated case of invasive rhinitis without sinusitis. Moreover, none of these patients had been treated with voriconazole and surgical microdebridement.

We present a case of invasive fungal rhinitis secondary to P lilacinus infection in an immunosuppressed patient who was successfully treated with voriconazole and endonasal microdebridement.

Case report

A 65-year-old woman with history of idiopathic pulmonary fibrosis and bilaterallung transplantation presented to the otolaryngology clinic with a 4-month history of left-sided purulent and sanguineous rhinorrhea. In addition, the patient reported a lump inside her left nasal vestibule. She denied facial pain, paresthesias, and nasal obstruction. Because of the double lung transplantation, her immune status was compromised, and she was taking tacrolimus at 1 mg twice daily and prednisone at 5 mg/day as an antirejection regimen.

Office nasal endoscopy revealed a thick, yellow, mucoid discharge within the nasal cavity as well as several small granulomatous lesions arising from the middle turbinate, inferior turbinate, nasal septum, and nasal vestibule on the left and from the middle turbinate on the right. Some superficial ulceration was seen on the lesions. Computed tomography of the sinus and maxillary areas revealed the presence of soft-tissue densities arising from the nasal septum; no evidence of invasion or bony erosion was seen.

Biopsies were taken and sent for culture and pathology. Pathology revealed an invasive fungal infection with septate hyphae, and microbiology confirmed the organism as P lilacinus. An infectious disease consult was immediately obtained. Based on that recommendation, the patient was started on oral voriconazole at 200 mg twice daily and immediately scheduled for surgical debridement.

In the operating room, the patient was positioned, prepped, and draped in the standard fashion for nasal endoscopy and sinus surgery. The nose was topically decongested with oxymetazoline pledgets and injected with lidocaine 1% with 1:100,000 epinephrine. After adequate vasoconstriction was achieved, a 0[degrees] endoscope was used to fully evaluate the nasal cavities bilaterally. On the left side, polypoid lesions were seen on the septal mucosa, inferior turbinate mucosa, nasal vestibule, and

middle turbinate. Wide debridement with a microdebrider (Medtronic Xomed; Jacksonville, Fla.) equipped with a 4-mm blade was performed around each lesion. A partial middle turbinectomy was performed on the left side because of extensive disease. In the right nasal cavity, polypoid disease was found along the middle turbinate septum and the inferior turbinate. Again, wide debridement down to healthy bleeding tissue was performed with the microdebrider. Adequate hemostasis was achieved with oxymetazoline pledgers.

Postoperatively, the patient was continued on a 5-month course of voriconazole, and she was followed in the otolaryngology clinic monthly. At 1 month postoperatively, she had remucosalized nicely, she exhibited no evidence of fungal infection, and a biopsy found no evidence of disease. One month after the cessation of voriconazole therapy, she remained infection-flee as confirmed by a repeat biopsy. She remained disease-free at further follow-up visits.

Discussion

Fungal rhinosinusitis usually presents in a host with impaired immune defenses. It can be invasive or noninvasive. Invasive forms are usually caused by the Rhizopus, Mucor, or Aspergillus species. In immunocompromised patients, a prolonged exposure to various environmental factors has led to an increase in the number of infections caused by P lilacinus, Fusarium species, Acremonium species, Trichosporon beigelii, Blastoschizomyces capitatus, Penicillium species, and other dematiaceous species. (13)

Paecilomyces species are ubiquitous nematophagous fungi that are found primarily in soil. They are used as a bionematicide to control nematodes that threaten crops. Their prevalence as a cause of infection has been increasing over the years, and it appears that both immunocompromised and immunocompetent persons are at risk.

Over the past 30 years, only 6 cases of Paecilomyces infection in the sinonasal tract have been reported in the literature. (8-12) Four of these involved the species that was isolated in our patient. In a 1980 case report, Rockhill and Klein told of an immunocompetent woman with chronic maxillary sinusitis caused by Plilacinus who was treated with tetracycline and a Caldwell-Luc procedure? In 1996, Gucalp et al reported a case of invasive fungal sinusitis in an immunocompromised patient with acute myeloid leukemia; the pathogen, which was identified as P lilacinus on culture, was resistant to amphotericin B, but the patient was effectively treated with itraconazole and surgery. (9) In 2000, Nayak et al described the case o fan immunocompetent child who presented with unilateral sinusitis and proptosis; endoscopic sinus surgery and 6 months of itraconazole were effective in eradicating the disease. (10)

To the best of our knowledge, our patient represents the first reported case of isolated P lilacinus rhinitis to be successfully treated with voriconazole and endonasal debridement with a microdebrider. In our patient, any areas that were deemed to be abnormal on intraoperatire nasal endoscopy were microdebrided with a shaver. Debridement was continued until healthy bleeding tissue was encountered. Care was taken to avoid unneeded mucosal damage. On our patient's left side, a large area of the middle turbinate was removed with endoscopic scissors. The voriconazole dosage of 200 mg twice a day orally was suggested by the infectious disease consultant, and the patient was started on this regimen immediately. She was treated for 5 months, and she remained disease- flee on endoscopic evaluation and clinical observation.

References

(1.) Hall VC, Goyal S, Davis MD, Walsh JS. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus: Report of three cases and review of the literature. Int J Dermato1 2004;43(9):648-53.

(2.) Carey J, D'Amico R, Sutton DA, Rinaldi MG. Paecilomyces lilacinus vaginitis in an immuno-competent patient. Emerg Infect Dis 2003;9(9):1155-8.

(3.) Garbino J, Ondrusova A, Baglivo E, et al. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002;34(9):701-3.

(4.) Chan-Tack KM, Thio CL, Miller NS, et al. Paecilomyces lilacinus fungemia in an adult bone marrow transplant recipient. Med Mycol 1999;37(1):57-60.

(5.) Fletcher CL, Hay RJ, Midgley G, Moore M. Onychomycosis caused by infection with Paecilomyces lilacinus. Br J Dermatol 1998;139(6): 1133-5.

(6.) Okhravi N, Dart JK, Towler HM, Lightman S. Paecilomyces lilacinus endophthalmitis with secondary keratitis: A case report and literature review. Arch Ophthalmol 1997; 115(10): 1320-4.

(7.) Westenfeld F, Alston WK, Winn WC. Complicated soft tissue infection with prepatellar bursitis caused by Paecilomyces lilacinus in an immunocompetent host: Case report and review. J Clin Microbiol 1996;34(6):1559-62.

(8.) Rockhill RC, Klein MD. Paecilomyces lilacinus as the cause of chronic maxillary sinusitis. J Clin Microbiol 1980;11(6):737-9.

(9.) Gucalp R, Carlisle P, Gialanella P, et al. Paecilomyces sinusitis in an immunocompromised adult patient: Case report and review. Clin Infect Dis 1996;23(2):391-3.

(10.) Nayak DR, Balakrishnan R, Nainani S, Siddique S. Paecilomyces fungus infection of the paranasal sinuses. Int J Pediatr Otorhinolaryngol 2000;52(2):183-7.

(11.) Rowley SD, Strom CG. Paecilomyces fungus infection of the maxillary sinus. Laryngoscope 1982;92(3):332-4.

(12.) Thompson RF, Bode RB, Rhodes JC, Gluckman JL. Paecilomyces variotii. An unusual cause of isolated sphenoid sinusitis. Arch Otolaryngol Head Neck Surg 1988;114(5):567-9.

(13.) Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996;22(Suppl 2):S112-18.

Shawn C. Ciecko, MD; Richard Scher, MD

From ENT and allergy Associates LLP, Staten Island, N.Y. (Dr. Ciecko); and the Division of Otolaryngology--Head and Neck Surgery, Department of Surgery, Duke University Medical Center, Durham, N.C. (Dr. Scher).

Corresponding author: Shawn C. Ciecko, MD, ENT and MlergyAssociates LLP, 1887 Richmond Ave., Suite 5, Staten Island, NY 10314. E-mail: shawnciecko@gmail.com
COPYRIGHT 2010 Vendome Group LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:ORIGINAL ARTICLE
Author:Ciecko, Shawn C.; Scher, Richard
Publication:Ear, Nose and Throat Journal
Article Type:Case study
Geographic Code:1USA
Date:Dec 1, 2010
Words:1397
Previous Article:Fluoroscopic localization of a retained intranasal ballistic foreign body in an unexpected location.
Next Article:Malignant peripheral nerve sheath tumor of the infratemporal fossa with intracranial extension.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters